Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment

Award Number: R01EY025717
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2016
PERIOD OF PERFORMANCE END DATE: 06/30/2021

Group Awards By:

View Award Description

Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment - DESCRIPTION (provided by applicant): Severe loss of vision occurs due to retinitis pigmentosa (RP) or age-related macular degeneration (AMD) when degeneration of photoreceptors in the eye occurs. This leads not only to physical impairment, but has a significant emotional and psychological impact on quality of life of the patients as well as family members. The current clinical treatment aimed at vision restoration in RP patients is invasive involving surgical procedure for retinal implants. However, these electrical stimulation based implants are limited by poor resolution, heat production (high current required for higher electrode density), retinal damage over a time period and cellular overgrowth due to surgical implantation. Currently, use of optogenetic sensitization of retinal cells has allowed possibilityof stimulating cells with single-cell resolution. In addition to higher resolution, optogenetics has several advantages over electrical stimulation such as cellular specificity and non-invasiveness. However, clinical translation of optogenetic enabled vision restoration suffers from two major drawbacks: (i) Narrow spectral sensitivity of opsin requiring active stimulation by blue light source having intensity order of magnitude higher than ambient light; and (ii) Lack of approach for controlled-delivery of opsin-encoding genes into spatially-targeted regions of degenerated-retina (e.g. periphery in RP and macula in AMD). To allow ambient- light based stimulation paradigm, we have developed broad-band opsin construct that has broad spectral excitability in the entire visible spectrum. This allows significantly higher sensitivity of broad-band opsin sensitized higher-order neurons in degenerated retina to ambient white light, and therefore, significantly lower activation-threshold in contrast to conventional approach of narrow-band opsin and/or use of intense, narrow- band light based active-stimulation. Further, we have developed a near-infrared (NIR) ultrafast laser-based transfection method and demonstrated non-viral, spatially-targeted expression of opsin(s) in retinal ganglion cell (RGC) layer. The overall objective of this project is to demonstrate enhanced retinal photosensitivity in mice model of RP, allowing bright ambient-level white-light stimulation of retinal ganglion cells, sensitized with broadband-opsin by targeted transfection using NIR ultrafast laser beam. Towards this goal we have following aims: (i) Development of broad-band opsin for wide-band efficient optogenetic stimulation; (ii) Optoporation of broad-band opsin encoding genes to spatially-targeted retinal ganglion cells; and (iii) Non-viral in-vivo optical delivery of plasmids encoding broad-band opsin into spatially-targeted regions of photo-degenerated retina of animal model. Success of this proposal will lead to a new clinical approach for treating patients with RP and AMD by determining degenerated areas, followed by conventional intravitreal injection of broad-band opsin constructs and NIR laser-assisted targeted, non-viral delivery of the constructs to degenerated areas in an efficient and minimally-invasive manner. We believe that such treatment will lead to restoration of high- resolution vision by white-light stimulation of broad-band opsin sensitized RGCs at ambient light level.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	NANOSCOPE TECHNOLOGIES LLC	1312 BROWN TRL	BEDFORD	TX	76022	TARRANT	USA	Vision Research	000	5	11/30/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $384,200 )
2020	2020	NANOSCOPE TECHNOLOGIES LLC	2519 RADCLIFFE DR	ARLINGTON	TX	76012	TARRANT	USA	Vision Research	000	5	8/28/2020	NON-COMPETING CONTINUATION	$384,200
														Subtotal = $384,200

Issue Date FY: 2019 ( Subtotal = $484,950 )
2019	2019	NANOSCOPE TECHNOLOGIES LLC	2519 RADCLIFFE DR	ARLINGTON	TX	76012	TARRANT	USA	Vision Research	000	4	6/20/2019	NON-COMPETING CONTINUATION	$484,950
														Subtotal = $484,950

Issue Date FY: 2018 ( Subtotal = $319,000 )
2018	2018	NANOSCOPE TECHNOLOGIES LLC	2519 RADCLIFFE DR	ARLINGTON	TX	76012	TARRANT	USA	Vision Research	000	3	7/12/2018	NON-COMPETING CONTINUATION	$247,500
2018	2018	NANOSCOPE TECHNOLOGIES LLC	2519 RADCLIFFE DR	ARLINGTON	TX	76012	TARRANT	USA	Vision Research	001	3	9/13/2018	SUPPLEMENT FOR EXPANSION	$71,500
														Subtotal = $319,000

Issue Date FY: 2017 ( Subtotal = $247,500 )
2017	2017	NANOSCOPE TECHNOLOGIES LLC	2519 RADCLIFFE DR	ARLINGTON	TX	76012	TARRANT	USA	Vision Research	000	2	6/19/2017	NON-COMPETING CONTINUATION	$247,500
														Subtotal = $247,500

Issue Date FY: 2016 ( Subtotal = $247,500 )
2016	2016	NANOSCOPE TECHNOLOGIES LLC	2519 RADCLIFFE DR	ARLINGTON	TX	76012	TARRANT	USA	Vision Research	000	1	6/28/2016	NEW	$247,500
														Subtotal = $247,500

Grand Total All Awards = $1,683,150

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment

Award Number: R01EY025717

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2016

PERIOD OF PERFORMANCE END DATE: 06/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer